what is glp-1 treatment GLP-1/ Weight Loss Injections GLP-1 Weight Loss NYC |
Description
Disclaimer: This article is for informational purposes only and is not medical advice
Composite kidney events were reported in 134 (38.2%) and 393 (44.2%) patients in the GLP-1RA and DPP-4i groups, respectively (subdistribution HR 0.72, 95% CI 0.560.93)
Compared with SGLT-2 inhibitor use, GLP-1 receptor agonist use was not associated with an increased risk of pulmonary aspiration (pooled risk ratio 0.98, 95% CI 0.73 to 1.31), although it was associated with a higher risk for discontinuation of endoscopy (1.99, 1.56 to 2.53)
Hear real patient stories, and how Nice Healthcare can support you at every step of your health journey.
Learn more about what to expect during the first week of treatment with these medications.
